nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—Reflexes abnormal—Hydrochlorothiazide—nephrolithiasis	0.188	0.192	CcSEcCtD
Frovatriptan—Feeling cold—Hydrochlorothiazide—nephrolithiasis	0.0549	0.056	CcSEcCtD
Frovatriptan—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.034	0.0347	CcSEcCtD
Frovatriptan—Toothache—Hydrochlorothiazide—nephrolithiasis	0.0258	0.0263	CcSEcCtD
Frovatriptan—Peptic ulcer—Hydrochlorothiazide—nephrolithiasis	0.0235	0.0239	CcSEcCtD
Frovatriptan—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0205	0.0209	CcSEcCtD
Frovatriptan—Numbness—Hydrochlorothiazide—nephrolithiasis	0.0189	0.0193	CcSEcCtD
Frovatriptan—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.0181	0.0185	CcSEcCtD
Frovatriptan—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.0174	0.0177	CcSEcCtD
Frovatriptan—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.0169	0.0172	CcSEcCtD
Frovatriptan—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.0164	0.0167	CcSEcCtD
Frovatriptan—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0157	0.016	CcSEcCtD
Frovatriptan—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.0142	0.0145	CcSEcCtD
Frovatriptan—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.013	0.0132	CcSEcCtD
Frovatriptan—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.0127	0.013	CcSEcCtD
Frovatriptan—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.0122	0.0124	CcSEcCtD
Frovatriptan—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.0121	0.0123	CcSEcCtD
Frovatriptan—Thirst—Hydrochlorothiazide—nephrolithiasis	0.012	0.0122	CcSEcCtD
Frovatriptan—Purpura—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0121	CcSEcCtD
Frovatriptan—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0116	CcSEcCtD
Frovatriptan—Migraine—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0114	CcSEcCtD
Frovatriptan—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0112	0.0114	CcSEcCtD
Frovatriptan—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0108	0.011	CcSEcCtD
Frovatriptan—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0109	CcSEcCtD
Frovatriptan—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.01	0.0102	CcSEcCtD
Frovatriptan—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00984	0.01	CcSEcCtD
Frovatriptan—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00909	0.00927	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00865	0.00882	CcSEcCtD
Frovatriptan—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.0086	0.00877	CcSEcCtD
Frovatriptan—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00853	0.0087	CcSEcCtD
Frovatriptan—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00828	0.00844	CcSEcCtD
Frovatriptan—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00823	0.0084	CcSEcCtD
Frovatriptan—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00802	0.00818	CcSEcCtD
Frovatriptan—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.0079	0.00806	CcSEcCtD
Frovatriptan—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00784	0.008	CcSEcCtD
Frovatriptan—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00782	0.00798	CcSEcCtD
Frovatriptan—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00759	0.00774	CcSEcCtD
Frovatriptan—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00735	0.00749	CcSEcCtD
Frovatriptan—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00731	0.00746	CcSEcCtD
Frovatriptan—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00704	0.00718	CcSEcCtD
Frovatriptan—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00676	0.00689	CcSEcCtD
Frovatriptan—Tension—Hydrochlorothiazide—nephrolithiasis	0.00673	0.00686	CcSEcCtD
Frovatriptan—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00672	0.00685	CcSEcCtD
Frovatriptan—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00666	0.00679	CcSEcCtD
Frovatriptan—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00663	0.00677	CcSEcCtD
Frovatriptan—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00659	0.00673	CcSEcCtD
Frovatriptan—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00643	0.00655	CcSEcCtD
Frovatriptan—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00636	0.00649	CcSEcCtD
Frovatriptan—Agitation—Hydrochlorothiazide—nephrolithiasis	0.0063	0.00643	CcSEcCtD
Frovatriptan—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00631	CcSEcCtD
Frovatriptan—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00616	0.00628	CcSEcCtD
Frovatriptan—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00615	0.00627	CcSEcCtD
Frovatriptan—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00606	0.00618	CcSEcCtD
Frovatriptan—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00603	0.00615	CcSEcCtD
Frovatriptan—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00584	0.00596	CcSEcCtD
Frovatriptan—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00584	0.00596	CcSEcCtD
Frovatriptan—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00584	0.00596	CcSEcCtD
Frovatriptan—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00582	0.00593	CcSEcCtD
Frovatriptan—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00577	0.00588	CcSEcCtD
Frovatriptan—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00571	0.00582	CcSEcCtD
Frovatriptan—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00564	0.00576	CcSEcCtD
Frovatriptan—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.0056	0.00571	CcSEcCtD
Frovatriptan—Shock—Hydrochlorothiazide—nephrolithiasis	0.00551	0.00562	CcSEcCtD
Frovatriptan—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00546	0.00557	CcSEcCtD
Frovatriptan—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00541	0.00552	CcSEcCtD
Frovatriptan—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00534	0.00544	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.0051	0.0052	CcSEcCtD
Frovatriptan—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00506	0.00516	CcSEcCtD
Frovatriptan—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00503	0.00513	CcSEcCtD
Frovatriptan—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00499	0.00509	CcSEcCtD
Frovatriptan—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00498	0.00508	CcSEcCtD
Frovatriptan—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00493	0.00503	CcSEcCtD
Frovatriptan—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00487	0.00496	CcSEcCtD
Frovatriptan—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00483	0.00492	CcSEcCtD
Frovatriptan—Pain—Hydrochlorothiazide—nephrolithiasis	0.00479	0.00488	CcSEcCtD
Frovatriptan—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00479	0.00488	CcSEcCtD
Frovatriptan—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00461	0.0047	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00458	0.00467	CcSEcCtD
Frovatriptan—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00442	0.00451	CcSEcCtD
Frovatriptan—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00442	0.00451	CcSEcCtD
Frovatriptan—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00412	0.00421	CcSEcCtD
Frovatriptan—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00402	0.0041	CcSEcCtD
Frovatriptan—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00396	0.00404	CcSEcCtD
Frovatriptan—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00383	0.00391	CcSEcCtD
Frovatriptan—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.0037	0.00378	CcSEcCtD
Frovatriptan—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00356	0.00363	CcSEcCtD
Frovatriptan—Headache—Hydrochlorothiazide—nephrolithiasis	0.00351	0.00358	CcSEcCtD
Frovatriptan—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00332	0.00339	CcSEcCtD
Frovatriptan—HTR1D—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00174	0.0886	CbGpPWpGaD
Frovatriptan—HTR1B—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0017	0.0868	CbGpPWpGaD
Frovatriptan—HTR1D—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00146	0.0745	CbGpPWpGaD
Frovatriptan—HTR1B—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00143	0.073	CbGpPWpGaD
Frovatriptan—HTR1A—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0013	0.0661	CbGpPWpGaD
Frovatriptan—HTR1A—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00109	0.0556	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—RGS14—nephrolithiasis	0.00074	0.0377	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000725	0.037	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—RGS14—nephrolithiasis	0.000552	0.0282	CbGpPWpGaD
Frovatriptan—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.000398	0.0203	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000335	0.0171	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.000328	0.0167	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000287	0.0147	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000281	0.0144	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—RGS14—nephrolithiasis	0.000253	0.0129	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00025	0.0128	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—RGS14—nephrolithiasis	0.000248	0.0126	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000233	0.0119	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—RGS14—nephrolithiasis	0.00023	0.0117	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—RGS14—nephrolithiasis	0.000225	0.0115	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CHRM3—nephrolithiasis	0.000219	0.0112	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000214	0.0109	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CHRM3—nephrolithiasis	0.000214	0.0109	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—PTH—nephrolithiasis	0.0002	0.0102	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—PTH—nephrolithiasis	0.000196	0.00999	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—RGS14—nephrolithiasis	0.000189	0.00963	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—RGS14—nephrolithiasis	0.000172	0.00875	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DGKH—nephrolithiasis	0.000171	0.00872	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DGKH—nephrolithiasis	0.000167	0.00854	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CHRM3—nephrolithiasis	0.000163	0.00832	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ADCY10—nephrolithiasis	0.00016	0.00815	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ADCY10—nephrolithiasis	0.000156	0.00798	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DGKH—nephrolithiasis	0.000155	0.00792	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DGKH—nephrolithiasis	0.000152	0.00776	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—PTH—nephrolithiasis	0.000149	0.00761	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—RGS14—nephrolithiasis	0.000136	0.00693	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—RGS14—nephrolithiasis	0.000133	0.00678	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DGKH—nephrolithiasis	0.000128	0.00651	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000124	0.00631	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000121	0.00618	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ADCY10—nephrolithiasis	0.000119	0.00608	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DGKH—nephrolithiasis	0.000116	0.00591	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—PTH—nephrolithiasis	0.000113	0.00577	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CHRM3—nephrolithiasis	0.000112	0.00573	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—PTH—nephrolithiasis	0.000111	0.00565	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CHRM3—nephrolithiasis	0.00011	0.00561	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—PTH—nephrolithiasis	0.000103	0.00524	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—RGS14—nephrolithiasis	0.000101	0.00517	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—PTH—nephrolithiasis	0.000101	0.00513	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CHRM3—nephrolithiasis	9.22e-05	0.0047	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DGKH—nephrolithiasis	9.18e-05	0.00468	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ATP6V0A4—nephrolithiasis	9.18e-05	0.00468	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DGKH—nephrolithiasis	8.98e-05	0.00458	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	8.98e-05	0.00458	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—PTH—nephrolithiasis	8.44e-05	0.0043	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CHRM3—nephrolithiasis	8.38e-05	0.00427	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—PTH—nephrolithiasis	7.66e-05	0.00391	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DGKH—nephrolithiasis	6.84e-05	0.00349	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.84e-05	0.00349	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CHRM3—nephrolithiasis	6.63e-05	0.00338	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CHRM3—nephrolithiasis	6.5e-05	0.00331	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—PTH—nephrolithiasis	6.07e-05	0.00309	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—PTH—nephrolithiasis	5.94e-05	0.00303	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—GRHPR—nephrolithiasis	5.26e-05	0.00268	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CHRM3—nephrolithiasis	4.95e-05	0.00252	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AGXT—nephrolithiasis	4.69e-05	0.00239	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—PTH—nephrolithiasis	4.53e-05	0.00231	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—APRT—nephrolithiasis	3.98e-05	0.00203	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	3.98e-05	0.00203	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—SPP1—nephrolithiasis	3.05e-05	0.00155	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—SPP1—nephrolithiasis	2.98e-05	0.00152	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AQP1—nephrolithiasis	2.84e-05	0.00145	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CHRM3—nephrolithiasis	2.57e-05	0.00131	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—SPP1—nephrolithiasis	2.27e-05	0.00116	CbGpPWpGaD
